oral first-in-class dual IDH1/IDH2 inhibitor efficacy in Ph. III for mIDH grade 2 gliomas, 40 mg QD from SBDD of prior mIDH inhibitor N. Engl. J. Med., June 4, 2023 Agios, Cambridge; Servier, Boston, MA